Abstract :

Polycystic Ovary syndrome (PCOS) is an underdiagnosed metabolic and endocrine disorder found in women of reproductive age in which ovaries develop follicles and does not release egg regularly. Its symptoms include menstrual irregularity, polycystic ovaries, hirsutism, infertility, insulin-resistance, impaired glucose tolerance. Currently the exact cause for the PCOS is unknown but research suggest that it may be related to lifestyle changes, environmental traits and genetical factors. Prevalence of PCOS in India ranges from 3.7 %to 22.5%. The syndrome is associated with increased gonadotropin-releasing diagnose PCOS till the date. , Rotterdam diagnostic criteria is highly accepted by the healthcare providers. Weight loss has been a major contributor in the non-pharmacological management of PCOS. Moderate exercise, behavioral therapy and psychological counselling is suggested for affected women. In pharmacological treatment, combined oral contraceptive pills (COCP), metformin, anti-androgen agents, clomiphene citrate, letrozole as fertility inducing agents are used and surgical options are also considered when necessary. In India, PCOS is still underdiagnosed disorder with long term morbidities involved and its time that it should be discussed more openly and treated holistically.

---

Keywords :

Diagnosis Guideline; Management; Polycystic Ovary Syndrome; Prevalence; Pathophysiology.

---

References :

1. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab. 2004 Jun;89(6):2745-9. doi: 10.1210/jc.2003-032046. PMID: 15181052.
2. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, Janssen OE, Legro RS, Norman RJ, Taylor AE, Witchel SF; Task Force on the Phenotype of the Polycystic Ovary Syndrome of The Androgen Excess and PCOS Society. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril. 2009 Feb;91(2):456-88. doi: 10.1016/j.fertnstert.2008.06.035. Epub 2008 Oct 23. PMID: 18950759.
3. Sharma, A., and M. Yousef. “Recent development in polycystic ovary syndrome IN: Progress in Obstetrics and Gynecology.” Edited by John Studd8 (2005): 227-239.
4. Johanson, R. B. “Clinical green top guidelines no. 20: the management of breech presentation. Royal College of Obstetricians and Gynaecologists, 2001.”
5. Daniilidis A, Dinas K. Long term health consequences of polycystic ovarian syndrome: a review analysis. Hippokratia. 2009;13(2):90-92.
6. Unluturk U, Harmanci A, Kocaefe C, Yildiz BO. The Genetic Basis of the Polycystic Ovary Syndrome: A Literature Review Including Discussion of PPAR-gamma. PPAR Res. 2007;2007:49109. doi:10.1155/2007/49109.
7. Nida Ajmal, Sanam Zeib Khan, Rozeena Shaikh,Polycystic ovary syndrome (PCOS) and genetic predisposition: A review article,European Journal of Obstetrics & Gynecology and Reproductive Biology: X,Volume 3,2019.
8. Skiba MA, Islam RM, Bell RJ, Davis SR. Understanding Variation in Prevalence Estimates of Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis. Hum Reprod Update(2018) 24:694–709.
9. Ganie MA, Vasudevan V, Wani IA, Baba MS, Arif T, Rashid A. Epidemiology, pathogenesis, genetics & management of polycystic ovary syndrome in India. Indian J Med Res. 2019;150(4):333-344. doi:10.4103/ijmr.IJMR_1937_17.
10. Balaji S, Amadi C, Prasad S, Bala Kasav J, Upadhyay V, Singh AK, Surapaneni KM, Joshi A. Urban rural comparisons of polycystic ovary syndrome burden among adolescent girls in a hospital setting in India. Biomed Res Int. 2015;2015:158951. doi: 10.1155/2015/158951. Epub 2015 Jan 5. PMID: 25629036; PMCID: PMC4299689.
11. Joshi B, Mukherjee S, Patil A, Purandare A, Chauhan S, Vaidya R. A cross-sectional study of polycystic ovarian syndrome among adolescent and young girls in Mumbai, India. Indian J Endocrinol Metab. 2014 May;18(3):317-24. doi: 10.4103/2230-8210.131162. PMID: 24944925; PMCID: PMC4056129.
12. Joseph N, Reddy AG, Joy D, Patel V, Santhosh P, Das S, Reddy SK. Study on the proportion and determinants of polycystic ovarian syndrome among health sciences students in South India. J Nat Sci Biol Med. 2016 Jul-Dec;7(2):166-72. doi: 10.4103/0976-9668.184704. PMID: 27433068; PMCID: PMC4934107.
13. Gill H, Tiwari P, Dabadghao P. Prevalence of polycystic ovary syndrome in young women from North India: A Community-based study. Indian J Endocrinol Metab. 2012 Dec;16(Suppl 2):S389-92. doi: 10.4103/2230-8210.104104. Erratum in: Indian J Endocrinol Metab. 2013 Jan;17(1):162. PMID: 23565440; PMCID: PMC3603088.
14. Nidhi R, Padmalatha V, Nagarathna R, Amritanshu R. Prevalence of polycystic ovarian syndrome in Indian adolescents. J Pediatr Adolesc Gynecol. 2011 Aug;24(4):223-7. doi: 10.1016/j.jpag.2011.03.002. Epub 2011 May 19. PMID: 21600812.
15. Vidya Bharathi R, Swetha S, Neerajaa J, Varsha Madhavica J, Janani DM, Rekha SN, et al. An epidemiological survey: Effect of predisposing factors for PCOS in Indian urban and rural population. Middle East Fertil Soc J. 2017;22:313–6.
16. Dumesic DA, Abbott DH, Sanchita S, Chazenbalk GD. Endocrine-Metabolic Dysfunction in Polycystic Ovary Syndrome: an Evolutionary Perspective. Curr Opin Endocr Metab Res 2020; 12:41-48.
17. Hoeger KM, Dokras A, Piltonen T. Update on PCOS: consequences, challenges, and guiding treatment. The Journal of Clinical Endocrinology & Metabolism. 2021 Mar;106(3):e1071-83.
18. McCartney CR, Marshall JC. Polycystic ovary syndrome. New England Journal of Medicine. 2016 Jul 7;375(1):54-64.
19. De Leo V, Musacchio MC, Cappelli V, et al. Genetic, hormonal and metabolic aspects of PCOS: an update. Reprod Biol Endocrinol 2016; 14:38.
20. Chen, Z. J. et al. Genome-wide association study identifies susceptibility loci for polycystic ovary syndrome on chromosome 2p16.3, 2p21 and 9q33.3. Nat. Genet. 43, 55–59 (2011).
21. Shi, Y. et al. Genome-wide association study identifies eight new risk loci for polycystic ovary syndrome. Nat. Genet. 44, 1020–1025 (2012).
22. Hayes, M. G. et al. Genome-wide association of polycystic ovary syndrome implicates alterations in gonadotropin secretion in European ancestry populations. Nat. Commun. 6, 7502 (2015).
23. Day, F. R. et al. Causal mechanisms and balancing selection inferred from genetic associations with polycystic ovary syndrome. Nat. Commun. 6, 8464 (2015).
24. Day, F. et al. Large-scale genome-wide meta-analysis of polycystic ovary syndrome suggests shared genetic architecture for different diagnosis criteria. PLoS Genet. 14, e1007813 (2018).
25. Kosova G, Uebanek M. Genetics of the polycystic ovary syndrome. Mol Cell Endocrinol 2013; 373:29–38.
26. Stener-Victorin E, Padmanabhan V, Walters KA, et al. Animal Models to Understand the Etiology and Pathophysiology of Polycystic Ovary Syndrome. Endocr Rev 2020; 41.
27. Risal S, Pei Y, Lu H, et al. Prenatal androgen exposure and transgenerational susceptibility to polycystic ovary syndrome. Nat Med 2019; 25:1894-1904.
28. Tata B, Mimouni NEH, Barbotin AL, et al. Elevated prenatal anti-Mullerian hormone reprograms the fetus and induces polycystic ovary syndrome in adulthood. Nat Med 2018; 24:834-846.
29. Piltonen TT, Giacobini P, Edvinsson A, et al. Circulating antimullerian hormone and steroid hormone levels remain high in pregnant women with polycystic ovary syndrome at term. Fertil Steril 2019; 111:588-596 el.
30. Legro RS, Arslanian SA, Ehrmann DA, et al.; Endocrine Society. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2013;98(12):4565-4592.
31. Zawadsky J, Dunaif A. Diagnostic criteria for polycystic ovary syndrome. In: Dunaif A, Givens JR, Haseltine FP, Merriam GR, editors. Polycystic ovary syndrome. Boston: Blackwell Scientific; 1992. pp. 377–384.
32. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004; 19:41–47.
33. Azziz R, Carmina E, Dewailly D, et al. Position statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab 2006; 91:4237–4245.
34. Badawy A, Elnashar A. Treatment options for polycystic ovary International journal of women’s health. 2011;3:25.
35. Akgul S, D € uzc € ¸eker Y, Kanbur N, Derman O. Do different diagnostic criteria cause impact polycystic ovary syndrome diagnosis for adolescents? J Pediatr Adolesc Gynecol 2017; doi.org/10.1016/j.jpag.2017.12.002.
36. Woolcock JG, Critchley HO, Munro MG, Broder MS, Fraser IS. Review of the confusion in current and historical terminology and definitions for disturbances of menstrual bleeding. Fertil Steril. 2008;90(6):2269-2280.
37. Smet M-E, McLennan A. Rotterdam criteria, the end. Australasian Journal of Ultrasound in Medicine. 2018;21(2):59-60. doi:10.1002/ajum.12096.
38. Rosenfield RL, Ehrmann DA. The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited. Endocrine Reviews. 2016;37(5):467-520. doi:10.1210/er.2015-1104.
39. Paramsothy P, Harlow SD, Greendale GA, et al. Bleeding patterns during the menopausal transition in the multi-ethnic Study of Women’s Health Across the Nation (SWAN): a prospective cohort study. Bjog 2014; 121:1564-73.
40. Davison SL, Bell R, Donath S, Montalto JG, Davis SR. Androgen levels in adult females: changes with age, menopause, and oophorectomy. J Clin Endocrinol Metab 2005; 90:3847- 53.
41. Wiweko B, Maidarti M, Priangga MD, et al. Antimullerian hormone as a diagnostic and prognostic tool for PCOS patients. J Assist Reprod Genet 2014; 31:1311–1316.
42. Iliodromiti S, Kelsey TW, Anderson RA, Nelson SM. Can anti-Mullerian hormone predict the diagnosis of polycystic ovary syndrome? A systematic review and meta-analysis of extracted data. J Clin Endocrinol Metab 2013; 98:3332–3340.
43. Dewailly, D. et al. Interactions between androgens, FSH, anti-Müllerian hormone and estradiol during folliculogenesis in the human normal and polycystic ovary. Hum. Reprod. Update 22, 709–724 (2016).
44. Hart R, Doherty DA, Norman RJ, et al. Serum antimullerian hormone (AMH) levels are elevated in adolescent girls with polycystic ovaries and the polycystic ovarian syndrome (PCOS). Fertil Steril 2010; 94:1118-21.
45. Ni, CM., Huang, WL., Jiang, YM. et al.Improving the accuracy and efficacy of diagnosing polycystic ovary syndrome by integrating metabolomics with clinical characteristics: study protocol for a randomized controlled trial. Trials 21, 169 (2020).
46. Meurer, L.N.; Kroll, A.P.; Jamieson, B.; Yousefi, P. Clinical inquiries: What is the best way to diagnose polycystic ovarian syndrome? J. Fam. Pract. 2006, 55, 351–352.
47. Kataoka J, Larsson I, Björkman S, Eliasson B, Schmidt J, Stener-Victorin E. Prevalence of polycystic ovary syndrome in women with severe obesity – Effects of a structured weight loss programme. Clin Endocrinol (Oxf). 2019 Dec;91(6):750-758. doi: 10.1111/cen.14098. Epub 2019 Oct 1. PMID: 31529511.
48. Sawant S, Bhide P. Fertility Treatment Options for Women With Polycystic Ovary Syndrome. Clin Med Insights Reprod Health. 2019;13:1179558119890867. Published 2019 Dec 27. doi:10.1177/1179558119890867.
49. Saleem F, Rizvi SW. New Therapeutic Approaches in Obesity and Metabolic Syndrome Associated with Polycystic Ovary Syndrome. Cureus. 2017;9(11):e1844. Published 2017 Nov 13. doi:10.7759/cureus.1844.
50. Che X, Chen Z, Liu M, Mo Z: Dietary Interventions: A Promising Treatment for Polycystic Ovary Syndrome. Ann Nutr Metab 2021;77:313-323. doi: 10.1159/000519302.
51. Turan V, Mutlu EK, Solmaz U, et al. Benefits of short-term structured exercise in non-overweight women with polycystic ovary syndrome: a prospective randomized controlled study. J Phys Ther Sci. 2015;27(7):2293-2297. doi:10.1589/jpts.27.2293.
52. Speelman DL. Nonpharmacologic Management of Symptoms in Females With Polycystic Ovary Syndrome: A Narrative Review. J Am Osteopath Assoc. 2019 Jan 1;119(1):25-39. doi: 10.7556/jaoa.2019.006. PMID: 30615039.
53. Teede HJ, Misso ML, Costello MF, Dokras A, Laven J, Moran L, Piltonen T, Norman RJ. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Human reproduction. 2018 Sep 1;33(9):1602-18.
54. Barthelmess EK, Naz RK. Polycystic ovary syndrome: current status and future perspective. Frontiers in bioscience (Elite edition). 2014;6:104.
55. Chugh RM, Park HS, El Andaloussi A, Elsharoud A, Esfandyari S, Ulin M, Bakir L, Aboalsoud A, Ali M, Ashour D, Igboeli P. Mesenchymal Stem Cell Therapy Ameliorates Metabolic Dysfunction and Restores Fertility in a PCOS Mouse Model Through Interleukin-10
56. Falsetti L, Gambera A, Platto C, Legrenzi L. Management of hirsutism. Am J Clin Dermatol. 2000;1(2):89–99
57. Grundy SM. Obesity, metabolic syndrome, and coronary atherosclerosis. Circulation. 2002;105(23):2696–2698
58. Venturoli S, Marescalchi O, Colombo FM, et al. A prospective randomized trial comparing low dose flutamide, finasteride, ketoconazole, and cyproterone acetate-estrogen regimens in the treatment of hirsutism. J Clin Endocrinol Metab. 1999;84(4):1304–1310.
59. Sahin Y, Dilber S, Keles¸timur F. Comparison of Diane 35 and Diane 35 plus finasteride in the treatment of hirsutism. Fertil Steril. 2001;75(3):496–500
60. Williams T, Mortada R, Porter S. Diagnosis and treatment of polycystic ovary syndrome. American family physician. 2016 Jul 15;94(2):106-13.
61. Legro RS, Barnhart HX, Schlaff WD, et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N Engl J Med. 2007;356(6):551–566
62. Palomba S, Zullo F, Diamanti-Kandarakis E, Orio F Jr. Surgery and laser diathermy. In: Diamanti-Kandarakis E, Nestler JE, Panidis D, Pasquali R, editors. Insulin Resistance and Polycystic Ovarian Syndrome. Totowa (NJ): Humana Press; 2007: Chap 33, 461–47.
63. Griesinger G, Diedrich K, Tarlatzis BC, Kolibianakis EM. GnRH-antagonists in ovarian stimulation for IVF in patients with poor response to gonadotrophins, polycystic ovary syndrome, and risk of ovarian hyperstimulation: a meta-analysis. Reprod Biomed Online. 2006;13(5):628–638
64. Cristello F, Cela V, Artini PG, Genazzani AR. Therapeutic strategies for ovulation induction in infertile women with polycystic ovary syndrome. Gynecol Endocrinol. 2005;21(6):340–352.
65. Haedersdal M, Wulf HC. Evidence-based review of hair removal using lasers and light sources. J Eur Acad Dermatol Venereol. 2006;20(1): 9–20.
66. Tabrizi FP, Hajizadeh-Sharafabad F, Vaezi M, Jafari-Vayghan H, Alizadeh M, Maleki V. Quercetin and polycystic ovary syndrome, current evidence and future directions: a systematic review. Journal of ovarian research. 2020 Dec;13(1):1-0.
67. Showell MG, Mackenzie-Proctor R, Jordan V, Hodgson R, Farquhar C. Inositol for subfertile women with polycystic ovary syndrome. Cochrane Database Syst Rev 2018; 12:CD012378.
68. Huber J, Walch K. Treating acne with oral contraceptives: use of lower doses. Contraception. 2006;73(1):23–29.